Dr. Ruben Mesa on Impact of New NCCN Guidelines for MPN

Ruben Mesa, MD
Published: Friday, Oct 07, 2016


Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).  
 
Prior to these guidelines management for MPN has been largely based on medical school teachings, review courses, and review articles, and European guidelines, says Mesa.
 
The NCCN guidelines are the first evidence-based, highly rigorous, U.S.-based guidelines. It will be very helpful in terms of clarifying a standard of care for insurance providers and CMS, but also in terms of improving quality and uniformity around treatment of myelofibrosis.

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).  
 
Prior to these guidelines management for MPN has been largely based on medical school teachings, review courses, and review articles, and European guidelines, says Mesa.
 
The NCCN guidelines are the first evidence-based, highly rigorous, U.S.-based guidelines. It will be very helpful in terms of clarifying a standard of care for insurance providers and CMS, but also in terms of improving quality and uniformity around treatment of myelofibrosis.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x